AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites.pdf

AdAlta (ASX:1AD), in partnership with La Trobe University, AdAlta has discovered an i-body® believed to be the first ever antibody-like molecule capable of high potency inhibition of malaria parasite invasion of red blood cells and liver cells across multiple strains of the parasite. This discovery demonstrates the versatility of the i-body® platform and potentially opening new avenues to malaria treatment.

The pre-print has been published and is under review by Nature Portfolio here: https://www.researchsquare.com/article/rs-3671797/v1

i-body®-Enabled Breakthrough in Malaria Treatment